Key result
Heart transplantation successfully managed progressive heart failure in a 32-year-old woman with catecholaminergic polymorphic ventricular tachycardia complicated by dilated cardiomyopathy.
Why the study?
CPVT is rarely associated with dilated cardiomyopathy, and the combination of both disease entities poses a major diagnostic and therapeutic challenge.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
This case highlights the diagnostic and therapeutic challenges of managing concurrent CPVT and dilated cardiomyopathy, which may ultimately require heart transplantation.
BACKGROUND: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a severe genetic arrhythmogenic disorder characterized by adrenergically induced ventricular tachycardia manifesting as stress-induced syncope and sudden cardiac death. While CPVT is not associated with dilated cardiomyopathy (DCM) in most cases, the combination of both disease entities poses a major diagnostic and therapeutic challenge. CASE SUMMARY: We present the case of a young woman with CPVT. The clinical course since childhood was characterized by repetitive episodes of exercise-induced ventricular arrhythmias and a brady-tachy syndrome due to rapid paroxysmal atrial fibrillation and sinus bradycardia. Medical treatment included propranolol and flecainide until echocardiography showed a dilated left ventricle with severely depressed ejection fraction when the patient was 32 years old. Cardiac magnetic resonance imaging revealed non-specific late gadolinium enhancement. Myocardial inflammation, however, was excluded by subsequent endomyocardial biopsy. Genetic analysis confirmed a mutation in the cardiac ryanodine receptor but no pathogenetic variant associated with DCM. Guideline-directed medical therapy for HFrEF was limited due to symptomatic hypotension. Over the next months, the patient developed progressive heart failure symptoms that were finally managed by heart transplantation. DISCUSSION: Management in patients with CPVT and DCM is challenging, as Class I antiarrhythmic drugs are not recommended in structural heart disease and prophylactic internal cardioverter-defibrillator implantation without adjuvant antiarrhythmic therapy can be detrimental. Regular echocardiographic screening for DCM is recommendable in patients with CPVT. A multidisciplinary team of heart failure specialists, electrophysiologists, geneticists, and imaging specialists is needed to collaborate in the delivery of clinical care.
No takes yet. Share an insight, caveat, or question.
Granitz et al. (2020) conducted a case report in Catecholaminergic polymorphic ventricular tachycardia and dilated cardiomyopathy (n=1). Heart transplantation was evaluated. Heart transplantation successfully managed progressive heart failure in a 32-year-old woman with catecholaminergic polymorphic ventricular tachycardia complicated by dilated cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: